JAK2 and primary myelofibrosis: Patients with intermediate-2 or high-risk primary myelofibrosis (PMF) on JAK2 inhibitors could have a worse outcome if they become infected with the virus; however, the effect of JAK inhibitors increasing of SARS-Cov-2 infection is unknown (23).